Time reports Hims stock rose 5% after the policy, while critics including Americans for Safe and Effective Medicines warn consumers are being treated like test subjects.
Recap by typeshit. Full story at Time Magazine.
Pharmacist Paige notes the second round of Medicare drug price negotiation starts January 1, 2027, with the semaglutide family on the list.
New generics and steady prices drove the jump in sales value, with Eli Lilly's tirzepatide leading the market.
Bloomberg reports that employer coverage of GLP-1 weight loss drugs is shrinking, leaving fewer US workers with access through their health plans.
UBS says volumes grew about 55% while net prices fell roughly 14%, and points to about 500,000 people joining Lilly's Medicare bridge program in a few months.
Healio
Speaking at OMED, Frye names melanotan as the riskiest, citing ED cases of priapism and rhabdomyolysis, and describes the BPC-157 and TB-500 Wolverine Stack.
Six people told the AP that HHS drove the policy with limited FDA input, and that it dropped a formal rule after staff raised safety concerns.
Loading…